BioArctic's Alzheimer's Drug Leqembi Iqlik Launched in US
BioArctic's partner Eisai has launched lecanemab-irmb subcutaneous injection, Leqembi Iqlik, in the US. The drug is approved for initiating treatment of early Alzheimer's disease and offers at-home administration.
Swedish company BioArctic AB's partner Eisai has launched a new formulation of its Alzheimer's disease treatment in the United States. Lecanemab-irmb subcutaneous injection, branded as Leqembi Iqlik in the US, received FDA approval on July 13, 2026.
The drug is now available for initiation therapy for patients in the early stages of Alzheimer's disease. Leqembi Iqlik is positioned as the first anti-amyloid treatment offering at-home dosing for both initiation and maintenance of therapy.
Administered via an autoinjector pen, Leqembi Iqlik provides a convenient alternative to intravenous infusions, potentially improving patient access and adherence to treatment. This development marks a step towards more accessible treatment options for early Alzheimer's.